Poujois Aurélia, Woimant France
Neurology Department, AP-HP, Lariboisière University Hospital, Paris, France.
National Reference Centre for Wilson Disease, AP-HP, Lariboisière University Hospital, Paris, France.
Ann Transl Med. 2019 Apr;7(Suppl 2):S67. doi: 10.21037/atm.2019.02.10.
The understanding and management of Wilson disease (WD) have dramatically improved since the first description of the disease by K. Wilson more than a century ago. However, the persistent long delay between the first symptoms and diagnosis emphasizes challenges in diagnosing earlier this copper overload disorder. As a treatable disease, WD should be detected early in the course of the disease by any health professionals at any care level, but the rare prevalence of the disease explains the lack of awareness of referring physicians. The most important challenge is to train physicians to recognize atypical or rare symptoms of WD that will lead to discuss the diagnosis more systematically. Atypia can come from the age of onset, the liver [non-alcoholic steatohepatitis (NASH) presentation], the central or peripheral nervous system (neuropathy, epilepsy, sleep disorders…) or may be due to lesions of other organs (renal manifestations, osteo-articular disorders or endocrine disturbances). Isolated biological anomalies, rare radiological findings or inadequate interpretation of copper test may also lead to misdiagnosis. The second challenge is to confirm the diagnosis faster and more effectively so as not to delay the initiation of treatment, and expand family screening as the genetic prevalence is higher than previously expected. Generalization of the exchangeable copper assay and the next generation sequencing (NGS) are two promising ways to overcome this ultimate challenge. By drawing attention to the earliest and rare symptoms and to new biomarkers and diagnostic tools, we hope that this article will increase diagnostic awareness and reduce delays so that patients can start their treatment earlier in the course of the illness and thus have a better disease prognosis.
自一个多世纪前K.威尔逊首次描述威尔逊病(WD)以来,对该病的认识和管理有了显著改善。然而,从首次出现症状到确诊之间长期持续的延迟凸显了在更早诊断这种铜过载疾病方面存在的挑战。作为一种可治疗的疾病,WD应在疾病过程中由任何护理层面的卫生专业人员尽早发现,但该病罕见的患病率解释了转诊医生对此缺乏认识的原因。最重要的挑战是培训医生识别WD的非典型或罕见症状,从而更系统地探讨诊断。非典型性可能源于发病年龄、肝脏[非酒精性脂肪性肝炎(NASH)表现]、中枢或周围神经系统(神经病变、癫痫、睡眠障碍等),也可能是由于其他器官的病变(肾脏表现、骨关节疾病或内分泌紊乱)。孤立的生物学异常、罕见的影像学表现或对铜测试的解读不当也可能导致误诊。第二个挑战是更快、更有效地确诊,以免延误治疗的开始,并扩大家族筛查,因为该病的遗传患病率高于先前预期。推广可交换铜测定法和下一代测序(NGS)是克服这一最终挑战的两种有前景的方法。通过关注最早出现的罕见症状以及新的生物标志物和诊断工具,我们希望本文能提高诊断意识并减少延误,以便患者能在疾病过程中更早开始治疗,从而获得更好的疾病预后。